Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SZSC:9989 Stock Report

Market Cap: HK$16.4b

Shenzhen Hepalink Pharmaceutical Group Balance Sheet Health

Financial Health criteria checks 5/6

Shenzhen Hepalink Pharmaceutical Group has a total shareholder equity of CN¥12.2B and total debt of CN¥4.2B, which brings its debt-to-equity ratio to 34.8%. Its total assets and total liabilities are CN¥18.1B and CN¥5.9B respectively.

Key information

34.8%

Debt to equity ratio

CN¥4.25b

Debt

Interest coverage ration/a
CashCN¥3.08b
EquityCN¥12.21b
Total liabilitiesCN¥5.91b
Total assetsCN¥18.12b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 9989's short term assets (CN¥10.4B) exceed its short term liabilities (CN¥4.3B).

Long Term Liabilities: 9989's short term assets (CN¥10.4B) exceed its long term liabilities (CN¥1.6B).


Debt to Equity History and Analysis

Debt Level: 9989's net debt to equity ratio (9.6%) is considered satisfactory.

Reducing Debt: 9989's debt to equity ratio has reduced from 91.2% to 34.8% over the past 5 years.

Debt Coverage: 9989's debt is well covered by operating cash flow (57.1%).

Interest Coverage: Insufficient data to determine if 9989's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies